TR200402276T2 - Nörotik düzensizliklerin tedavisi - Google Patents

Nörotik düzensizliklerin tedavisi

Info

Publication number
TR200402276T2
TR200402276T2 TR2004/02276T TR200402276T TR200402276T2 TR 200402276 T2 TR200402276 T2 TR 200402276T2 TR 2004/02276 T TR2004/02276 T TR 2004/02276T TR 200402276 T TR200402276 T TR 200402276T TR 200402276 T2 TR200402276 T2 TR 200402276T2
Authority
TR
Turkey
Prior art keywords
treatment
disorder
neurotic disorders
anxiety disorder
neurotic
Prior art date
Application number
TR2004/02276T
Other languages
English (en)
Turkish (tr)
Inventor
Sanchez Connie
Hogg Sandra
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200402276(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of TR200402276T2 publication Critical patent/TR200402276T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
TR2004/02276T 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi TR200402276T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08
PCT/DK2000/000377 WO2001003694A1 (en) 1999-07-08 2000-07-07 Treatment of neurotic disorders

Publications (1)

Publication Number Publication Date
TR200402276T2 true TR200402276T2 (tr) 2005-01-24

Family

ID=8099796

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2004/02276T TR200402276T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi
TR2004/02275T TR200402275T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi
TR2002/00014T TR200200014T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi.
TR2004/02277T TR200402277T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi

Family Applications After (3)

Application Number Title Priority Date Filing Date
TR2004/02275T TR200402275T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi
TR2002/00014T TR200200014T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi.
TR2004/02277T TR200402277T2 (tr) 1999-07-08 2000-07-07 Nörotik düzensizliklerin tedavisi

Country Status (38)

Country Link
US (6) US7271194B2 (enExample)
EP (4) EP1440691A3 (enExample)
JP (1) JP4773011B2 (enExample)
KR (1) KR100604176B1 (enExample)
CN (1) CN1198610C (enExample)
AR (1) AR021155A1 (enExample)
AT (1) ATE339955T1 (enExample)
AU (6) AU782514B2 (enExample)
BG (4) BG110467A (enExample)
BR (1) BR0011578A (enExample)
CA (4) CA2687392A1 (enExample)
CL (3) CL2008003941A1 (enExample)
CO (1) CO5190674A1 (enExample)
CY (1) CY1105806T1 (enExample)
CZ (1) CZ200270A3 (enExample)
DE (1) DE60030861T2 (enExample)
DK (1) DK1200081T3 (enExample)
EA (1) EA006555B1 (enExample)
ES (1) ES2272298T3 (enExample)
HK (1) HK1048069B (enExample)
HR (1) HRP20010820A2 (enExample)
HU (1) HUP0201791A3 (enExample)
IL (5) IL146131A0 (enExample)
IS (1) IS6137A (enExample)
ME (2) MEP2508A (enExample)
MX (1) MXPA01011626A (enExample)
MY (1) MY143278A (enExample)
NO (4) NO329021B1 (enExample)
PL (1) PL352030A1 (enExample)
PT (1) PT1200081E (enExample)
SI (1) SI1200081T1 (enExample)
SK (1) SK82002A3 (enExample)
TR (4) TR200402276T2 (enExample)
TW (1) TWI232101B (enExample)
UA (1) UA77645C2 (enExample)
WO (1) WO2001003694A1 (enExample)
YU (1) YU78701A (enExample)
ZA (1) ZA200108856B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
BR0113011A (pt) * 2000-07-21 2003-07-01 Lundbeck & Co As H Novos compostos e sua utilização como inibidores de transporte de glicina; composição farmacêutica e método do tratamento
CN1509169A (zh) * 2001-05-01 2004-06-30 H��¡�±������޹�˾ 对映体纯艾司西酞普兰的用途
ES2233842T3 (es) 2001-07-31 2005-06-16 H. Lundbeck A/S Composicion cristalina que contiene escitalopram.
WO2004004721A1 (en) * 2002-07-08 2004-01-15 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
MXPA05005772A (es) * 2002-12-23 2005-08-16 Lundbeck & Co As H Bromhidrato de escitalopram y un metodo para su preparacion.
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2272514A1 (en) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2625835A1 (en) 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (enExample) 1965-03-18
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4436874A (en) 1981-11-19 1984-03-13 Societe D'expansion Scientifique "Expansia" Acrylic copolymers and their use in solid phase peptide synthesis
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DK213290D0 (da) 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
WO1993009769A1 (en) 1991-11-15 1993-05-27 Sepracor, Inc. Methods and compositions utilizing pure s(+) isomer fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
DK0759299T3 (da) 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
UA62984C2 (en) * 1997-11-11 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
DK0957099T3 (da) * 1998-04-15 2003-03-17 Pfizer Prod Inc Heterocykliske carboxamider
JP2002519321A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
DE69935331T2 (de) 1998-07-13 2007-10-31 NPS Pharmaceuticals, Inc., Salt Lake City Verfahren und verbindungen zur behandlung der depression
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
CA2337507A1 (en) 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SK285719B6 (sk) * 1998-10-20 2007-07-06 H. Lundbeck A/S Spôsob prípravy citalopramu a medziprodukty
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
EP1173431B2 (en) * 1999-04-14 2009-08-26 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
EP1276478A2 (en) 2000-04-24 2003-01-22 ARYx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
CN1509169A (zh) * 2001-05-01 2004-06-30 H��¡�±������޹�˾ 对映体纯艾司西酞普兰的用途

Also Published As

Publication number Publication date
IL170193A (en) 2010-04-29
US20070276035A1 (en) 2007-11-29
HRP20010820A2 (en) 2003-08-31
BG110468A (en) 2010-01-29
CA2687392A1 (en) 2001-01-18
US20040029957A1 (en) 2004-02-12
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
AU2005202686A1 (en) 2005-07-14
UA77645C2 (en) 2007-01-15
US20020086899A1 (en) 2002-07-04
CN1198610C (zh) 2005-04-27
HK1048069A1 (en) 2003-03-21
CL2008003939A1 (es) 2009-06-05
HK1048069B (zh) 2005-12-16
AU782514B2 (en) 2005-08-04
NO329021B1 (no) 2010-07-26
TR200402277T2 (tr) 2005-01-24
BG106279A (bg) 2002-08-30
AU2005202686B2 (en) 2009-01-15
IS6137A (is) 2001-10-30
IL146131A (en) 2007-02-11
ME00032B (me) 2010-02-10
AR021155A1 (es) 2002-06-12
BR0011578A (pt) 2002-03-26
IL170192A (en) 2010-04-29
WO2001003694A1 (en) 2001-01-18
DE60030861T2 (de) 2007-05-03
SK82002A3 (en) 2002-07-02
EP1200081A1 (en) 2002-05-02
AU2008264182A1 (en) 2009-01-29
NO20100334L (no) 2002-01-07
ES2272298T3 (es) 2007-05-01
CZ200270A3 (cs) 2002-04-17
EP1440689A2 (en) 2004-07-28
CY1105806T1 (el) 2011-02-02
CA2687394A1 (en) 2001-01-18
JP4773011B2 (ja) 2011-09-14
YU78701A (sh) 2004-03-12
EP1440690A2 (en) 2004-07-28
BG110466A (en) 2010-01-29
PT1200081E (pt) 2007-01-31
MY143278A (en) 2011-04-15
BG110467A (en) 2010-01-29
ATE339955T1 (de) 2006-10-15
ZA200108856B (en) 2002-12-24
CA2373757A1 (en) 2001-01-18
MXPA01011626A (es) 2002-06-04
TR200200014T2 (tr) 2002-05-21
CO5190674A1 (es) 2002-08-29
CN1360501A (zh) 2002-07-24
TR200402275T2 (tr) 2005-03-21
CL2008003938A1 (es) 2009-05-22
US20040029956A1 (en) 2004-02-12
EP1440690A3 (en) 2004-08-18
EP1440689A3 (en) 2004-08-25
US20040029958A1 (en) 2004-02-12
EA006555B1 (ru) 2006-02-24
AU2005202685B2 (en) 2009-01-15
US7265151B2 (en) 2007-09-04
TWI232101B (en) 2005-05-11
CA2373757C (en) 2010-01-05
IL146131A0 (en) 2002-07-25
AU2008264188A1 (en) 2009-05-07
HUP0201791A2 (en) 2002-10-28
AU2005202685A1 (en) 2005-07-14
AU5806100A (en) 2001-01-30
US7271194B2 (en) 2007-09-18
NO20100335L (no) 2002-01-07
PL352030A1 (en) 2003-07-28
HUP0201791A3 (en) 2005-02-28
EP1440691A3 (en) 2004-08-25
US20050101665A1 (en) 2005-05-12
US6960613B2 (en) 2005-11-01
DK1200081T3 (da) 2006-12-27
CA2687396A1 (en) 2001-01-18
EP1200081B1 (en) 2006-09-20
MEP2508A (xx) 2010-02-10
NO20100333L (no) 2002-01-07
AU2005202684A1 (en) 2005-07-14
EP1440691A2 (en) 2004-07-28
NO20020062D0 (no) 2002-01-07
KR100604176B1 (ko) 2006-07-25
AU2005202684B2 (en) 2009-01-15
EA200200137A1 (ru) 2002-06-27
CL2008003941A1 (es) 2009-05-22
KR20020015346A (ko) 2002-02-27
DE60030861D1 (de) 2006-11-02
IL170194A (en) 2010-05-31
JP2003504332A (ja) 2003-02-04

Similar Documents

Publication Publication Date Title
TR200402277T2 (tr) Nörotik düzensizliklerin tedavisi
PL375621A1 (pl) Kompozycje farmaceutyczne zawierające flawonoidy i mentol
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
AR034746A1 (es) Combinaciones para el tratamiento de trastornos inflamatorios
GEP20053602B (en) Aripiprazole for Oral Administration
TR200002739T2 (tr) Üst solunum problemlerinin tedavisinde ksilitol kompozisyonları
BR9814375A (pt) Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas
EE05196B1 (et) Heteroarlsulfonlklgahelaga antraniilamiidid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad ravimpreparaadid
CY1109238T1 (el) Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη
PT1228028E (pt) Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
BR0315437A (pt) Composição para o tratamento dos cabelos, usos da mesma e método para o tratamento dos cabelos
ATE318610T1 (de) Orale zusammensetzungen zur behandlung von kopfhauterkrankungen
AR034493A1 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
BR0210650A (pt) Tablete, e, uso do mesmo
DE50110618D1 (de) Verwendung von MEK-Inhibitoren zur Herstellung eines Arzneimittels gegen Negativstrang-RNA-Viren Infektionen
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
BR0214060A (pt) Uso de monoidroxicarbamazepina em distúrbio afetivo e de atenção e dor neuropática
DK1212072T3 (da) Farmaceutisk præparat omfattende eukalyptus- og orangeolie
HRP20050580A2 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
BR0007491A (pt) Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções
DE50207436D1 (de) Verwendung von 5-substituierten nukleosiden und/oder deren prodrugs zur resistenzfreien therapie von infektionskrankheiten
PT1206267E (pt) Medicamentos contendo oligo-ou/e polirribonucleotidos xenogenicos